Back to Clinical Trials

Brief Title: Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer

INTRODUCTION

  • Org Study ID: NCI-2018-03264
  • Secondary ID: NCI-2018-03264, S1806, S1806, U10CA180888
  • NTC ID: NCT03775265
  • Sponsor: National Cancer Institute (NCI)

BRIEF SUMMARY

This phase III trial studies how well chemotherapy and radiation therapy work with or without atezolizumab in treating patients with localized muscle invasive bladder cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving atezolizumab with radiation therapy and chemotherapy may work better in treating patients with localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy without atezolizumab.

DETAILED DESCRIPTION

PRIMARY OBJECTIVE:

I. To compare bladder intact event-free survival (BI-EFS) for concurrent chemoradiation therapy (CRT) with and without atezolizumab in localized muscle invasive bladder cancer (MIBC).

SECONDARY OBJECTIVES:

I. To compare overall survival between the two arms. II. To compare modified bladder intact event-free survival including cancer related death between arms.

III. To compare complete and partial pathologic response between arms at 3 months after completing chemoradiation therapy.

IV. To estimate metastases-free survival by arm. V. To compare the qualitative and quantitative adverse events from each arm. VI. To estimate the rate of non-muscle invasive bladder cancer recurrence by arm.

VII. To estimate the rate of salvage cystectomy and reasons for cystectomy by arm.

VIII. To compare mean patient-reported global quality of life (QOL) at week 54 using the European Organization for Research and Treatment (EORTC) Quality of Life Questionnaire (QLQ)-Core (C)30 Global Health Status (GHS) subscale score between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus (vs.) without atezolizumab.

TRANSLATIONAL MEDICINE OBJECTIVES:

I. To test the hypothesis that a panel of validated biomarkers of concurrent CRT involving nuclear MRE11, impaired deoxyribonucleic acid damage response (DDR) function and tumor subtyping will be prognostic for BI-EFS among patients receiving either concurrent CRT or chemoimmuno-radiotherapy (CIRT) of the primary tumor.

II. To test the hypothesis that tumor total mutation burden, neoantigen burden, infiltrating immune response, PD-L1 expression and T cell response are associated with augmented response after concurrent CIRT.

III. To bank urine specimens for future use.

PATIENT-REPORTED OUTCOMES (PROs) OBJECTIVES:

I. To compare mean patient-reported global QOL as measured by the EORTC QLQ-C30 Global Health Status subscale scores at week 54 between patients with localized muscle-invasive bladder cancer randomized to chemoradiation with versus without atezolizumab. (Primary) II. To compare mean patient-reported bowel symptoms at each assessment time by arm using the Expanded Prostate Cancer Index Composite (EPIC) Bowel Assessment from the Expanded Prostate Index, the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-Muscle Invasive Bladder Cancer (BLM30), the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EuroQol Five Dimension Five Level Scale (EQ-5D-5L). (Exploratory) III. To compare longitudinal change over time by arm in patient-reported global QOL using the EORTC QLQ-C30, the Bowel Domain of the Expanded Prostate Index (EPIC Bowel Assessment), the bladder-specific supplement to the QLQ-C30, the EORTC QLQ-BLM30, the Physical Functioning subscale of the EORTC QLQ-C30, and overall health status using the EQ-5D-5L. (Exploratory)

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients undergo radiation therapy (RT) (3 dimensional [D] CRT or intensity-modulated radiation therapy [IMRT]) Monday-Friday for up to 7 weeks. Patients also receive chemotherapy based on physician's choice of gemcitabine intravenously (IV) twice weekly for 6 weeks, or cisplatin IV weekly for 6 weeks concurrent with RT, or fluorouracil IV on same days as doses 1-5 and 16-20 of radiation therapy, and mitomycin IV on day 1 of radiation therapy in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo RT (3DCRT or IMRT) Monday-Friday for up to 7 weeks and receive chemotherapy based on physician's choice as in Arm I. Patients also receive atezolizumab IV over 60 minutes on day 1 of chemotherapy. Treatment repeats every 21 days for a total of 6 months (9 doses total) in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 3 months for 2 years, then every 6 months for 3 years.

  • Overall Status
    Recruiting
  • Start Date
    April 19, 2019
  • Phase
    Phase 3
  • Study Type
    Interventional

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Bladder intact event-free survival (BI-EFS)

Primary Outcome 1 - Timeframe: From the date of randomization to the first documentation of a BI-EFS event, assessed up to 5 years

CONDITION

  • Bladder Urothelial Carcinoma
  • Muscle Invasive Bladder Carcinoma
  • Stage II Bladder Cancer AJCC v8
  • Stage III Bladder Cancer AJCC v8
  • Stage IIIA Bladder Cancer AJCC v8

ELIGIBILITY

Inclusion Criteria:
STEP 1 REGISTRATION:

- If this will be the first patient from a registering site to receive a given RT modality (3DCRT vs. IMRT), the site must first submit pre-RT planning documents within 3 days of Step 1 registration and receive approval from Imaging and Radiation Oncology Core (IROC) before randomizing the patient to Step 2. If this will not be the first patient to receive a specific RT modality, the patient should be immediately randomized to Step 2 on the same day.

- STEP 2 RANDOMIZATION

- If patient required review of pre-RT planning, randomization must occur within 14 days of initial registration.

- Patients must have histologically proven, T2-T4a N0M0 urothelial carcinoma of the bladder within 120 days prior to randomization and no intervening treatment between the histologic proof and randomization. Patients with mixed urothelial carcinoma will be eligible for the trial, but the presence of small cell carcinoma will make a patient ineligible. Patients with lymph nodes >= 1.0 cm in shortest cross-sectional diameter on imaging (computed tomography [CT]/magnetic resonance imaging [MRI] of abdomen and pelvis) must have a biopsy of the enlarged lymph node showing no tumor involvement within 70 days prior to randomization. These patients may be suitable for neoadjuvant chemotherapy and radical cystectomy and are eligible for this trial if they seek out a bladder sparing treatment strategy, however patients who have received prior systemic chemotherapy for bladder cancer are not eligible for the trial.

- Patients must undergo a transurethral resection of bladder tumor (TURBT) within 70 days prior to randomization. In a situation where a patient is referred from outside to the enrolling institution, patient must have a repeat office cystoscopy by the urologist who will be following the patient on the clinical trial to assess the adequacy of the prior TURBT. This cystoscopy can be performed in urologist office without general anesthesia. Patient may then undergo repeat TURBT if deemed necessary as standard of care by the treating urologist. Patients may have either completely or partially resected tumors as long as the treating urologist attempted maximal resection. Patient must not have T4b disease

- Patients must undergo radiological staging within 70 days prior to randomization. Imaging of chest, abdomen, and pelvis must be performed using CT or MRI. Patients must not have evidence of T4bN1-3 disease. Eligibility is based on the local radiology report.

- Patients with hydronephrosis are eligible if they have unilateral hydronephrosis and kidney function meets criteria specified.

- Patient must be planning to receive one of the protocol specified chemotherapy regimens.

- All adverse events associated with any prior surgery and intravesical therapy must have resolved to Common Terminology Criteria for Adverse Events (CTCAE) grade =< 2 prior to randomization. - Patient may or may not be radical cystectomy candidates. - Absolute neutrophil count (ANC) >=1,500/microliter (mcL) (within 28 days prior to randomization).

- Platelets >= 100,000/mcL (within 28 days prior to randomization).

- Hemoglobin >= 9 g/dL (within 28 days prior to randomization).

- Total bilirubin =< 1.5 x institutional upper limit of normal (IULN) (except patients with Gilbert's syndrome, who must have a total bilirubin < 3.0 mg/dL) (within 28 days prior to randomization). - Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) < 2.5 x IULN (within 28 days prior to randomization). - Patients must have adequate renal function as evidenced by calculated creatinine clearance >= 25 mL/min. The creatinine used to calculate the clearance result must have been obtained within 28 days prior to randomization.

- Patients must have Zubrod performance status =< 2. - Patients must have a baseline electrocardiography (ECG) performed within 30 days prior to randomization.
If patient has a known history of hepatitis B virus (HBV) or hepatitis C virus (HCV), they must meet the following criteria within 28 days prior to randomization.
Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen [HBsAg] test and a positive anti-HBc [antibody to hepatitis B core antigen] antibody test) are eligible.

- Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV ribonucleic acid (RNA).
Patients who are known to be positive for human immunodeficiency virus (HIV) are eligible only if they have all of the following:
A stable regimen of highly active anti-retroviral therapy (HAART)

- No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections

- A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard PCR-based tests within 28 days prior to randomization.

- No other prior malignancy is allowed except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease free for two years. Patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.

- Female patients of childbearing potential must have a serum pregnancy test prior to randomization. Patients must not be pregnant or nursing due to the potential teratogenic side effects of the protocol treatment. Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of protocol treatment, and for 5 months (150 days) after the last dose of all study drugs. A woman is considered to be of "reproductive potential" if she has had a menses at any time in the preceding 12 consecutive months.

- Patients must be offered the opportunity to participate in specimen banking for future studies.

- Patients who can complete Patient-Reported Outcome instruments in English or Spanish must agree to complete the EORTC QLQ-C30, the EORTC QLQ-BLM30, the EPIC Bowel Assessment, and the EQ-5D-5L per protocol schedule of assessment.

- As a part of the Oncology Patient Enrollment Network (OPEN) registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
Exclusion Criteria:
STEP 2 RANDOMIZATION EXCLUSION CRITERIA

- Patients must not have had urothelial carcinoma or histological variant at any site outside of the urinary bladder within the previous 24 months except Ta/T1/carcinoma in situ (CIS) of the upper urinary tract including renal pelvis and ureter if the patient had undergone complete nephroureterectomy.

- Patients must not have diffuse CIS based on cystoscopy and biopsy.

- Patient must not have received any systemic chemotherapy for their bladder cancer.

- Patient must not have had prior pelvic radiation.

- Patients must not have received prior treatment for muscle invasive bladder cancer including neoadjuvant chemotherapy for the current tumor.

- Patients must not have received any systemic therapy (including, but not limited to, interferon alfa-2b, high dose IL-2, pegylated interferon [PEG-IFN], anti-PD-1, anti-PD-L1), for non-muscle invasive bladder cancer. Prior intravesical BCG, interferon, and intravesical chemotherapy are allowed.
Patients must not have received any of the following prohibited therapies within 28 days prior to randomization or be planning to receive any of the following prohibited therapies during protocol treatment:
Anti-cancer systemic chemotherapy or biological therapy not specified in the protocol.

- Immunotherapy not specified in this protocol.

- Systemic or intravesical use of any non-study anti-cancer agent (investigational or non-investigational).

- Investigational agents other than atezolizumab.

- Live vaccines: Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, shingles, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g. Flu-Mist) are live attenuated vaccines, and are not allowed. Prior administration of intravesical BCG is allowed.

- Glucocorticoids for any purpose other than to modulate symptoms from an event of suspected immunologic etiology. The use of physiologic doses of corticosteroids (defined as 10 mg prednisone) are acceptable, however site investigators should consult with the study chair for any dose higher than 10 mg prednisone. Dexamethasone 4 mg iv with chemotherapy to prevent nausea is allowed.

- RANKL infusion: Concurrent denosumab (which binds the cytokine RANKL) for any known indication is prohibited due to interaction with study medication.

- Patients must not have a major surgical procedure within 28 days prior to randomization. If patient had any surgical procedure then they should have recovered to full presurgical performance status and surgical adverse events should have resolved to grade =< 2. TURBT is not considered a major surgical procedure.
Patients must not have received treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor [anti-TNF] agents) within 14 days prior to randomization. Exceptions:
Patients may have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea).

- The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed. Physiological doses equivalent of 10 mg prednisone daily are allowed. Short term steroids given as antiemetic therapy, e.g. 4 mg dexamethasone or equivalent once a week, is allowed.
Patients must not have received a live, attenuated vaccine within 4 weeks prior to randomization or anticipate that such a live, attenuated vaccine will be required while on protocol treatment and up to 5 months after the last dose of protocol treatment.
Inactivated influenza vaccination should be given during influenza season only (approximately October to March). Patients must not receive live, attenuated influenza vaccine within 4 weeks prior to randomization or while on protocol treatment and up to 5 months after the last dose of protocol treatment.

- Patients must not have undergone prior allogeneic bone marrow transplantation or prior solid organ transplantation.

- Patients must not have clinically significant liver disease that precludes patient from treatment regimens prescribed on the study (including, but not limited to, active viral, alcoholic or other autoimmune hepatitis, cirrhosis or inherited liver disease).

- Patient must not have history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis.

- Patients must not have an active infection requiring oral or IV antibiotics within 14 days prior to randomization. Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease) are not eligible. If patient develops urinary tract infection after TURBT they must have recovered from the infection prior to registration.

- Patients must not have active autoimmune disease that has required systemic treatment in past two years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Autoimmune diseases include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Bell's palsy, Guillain-Barre syndrome, multiple sclerosis, autoimmune thyroid disease, vasculitis, Graves' disease treated with methimazole or glomerulonephritis.

- Patient must not have a history of active tuberculosis.

- Patients must not be known to be allergic to Chinese hamster egg or ovary cell products and must not have any known major allergic reactions to any study drug.

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Parminder Singh

Role: Principal Investigator

Affiliation: Southwest Oncology Group

Overall Contact

Name: Parminder Singh

Phone: N/A

Email: N/A

LOCATION

Facility Status Contact
Facility: Mayo Clinic Hospital in Arizona
Phoenix, Arizona 85054
United States
Status: Recruiting Contact: Contact
Site Public Contact
855-776-0015
bernicl@sutterhealth.org
Facility: Mayo Clinic in Arizona
Scottsdale, Arizona 85259
United States
Status: Recruiting Contact: Principal Investigator
Parminder Singh
855-776-0015
cancercto@ucsd.edu
Facility: Alta Bates Summit Medical Center-Herrick Campus
Berkeley, California 94704
United States
Status: Recruiting Contact: Contact
Site Public Contact
323-865-0451
bernicl@sutterhealth.org
Facility: UC San Diego Moores Cancer Center
La Jolla, California 92093
United States
Status: Recruiting Contact: Principal Investigator
Edmund W. Tai
323-865-0451
bernicl@sutterhealth.org
Facility: Los Angeles County-USC Medical Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Contact
Site Public Contact
310-423-8965
ResearchInstituteInquiries@CommonSpirit.org
Facility: USC / Norris Comprehensive Cancer Center
Los Angeles, California 90033
United States
Status: Recruiting Contact: Principal Investigator
Tyler Stewart
530-749-4400
info@westernstatesncorp.org
Facility: Cedars Sinai Medical Center
Los Angeles, California 90048
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-827-8839
protocols@swog.org
Facility: Fremont - Rideout Cancer Center
Marysville, California 95901
United States
Status: Recruiting Contact: Principal Investigator
Leslie Ballas
415-209-2686
protocols@swog.org
Facility: UC Irvine Health/Chao Family Comprehensive Cancer Center
Orange, California 92868
United States
Status: Recruiting Contact: Contact
Site Public Contact
415-209-2686
canceranswers@yale.edu
Facility: Palo Alto Medical Foundation Health Care
Palo Alto, California 94301
United States
Status: Recruiting Contact: Principal Investigator
Leslie Ballas
415-209-2686
canceranswers@yale.edu
Facility: Sutter Roseville Medical Center
Roseville, California 95661
United States
Status: Recruiting Contact: Contact
Site Public Contact
916-734-3089
canceranswers@yale.edu
Facility: Sutter Medical Center Sacramento
Sacramento, California 95816
United States
Status: Recruiting Contact: Principal Investigator
Michael A. Ahdoot
805-219-4673
Dmiskin@Beebehealthcare.org
Facility: University of California Davis Comprehensive Cancer Center
Sacramento, California 95817
United States
Status: Recruiting Contact: Contact
Site Public Contact
720-848-0650
mhayden@christianacare.org
Facility: Pacific Central Coast Health Center-San Luis Obispo
San Luis Obispo, California 93401
United States
Status: Recruiting Contact: Principal Investigator
Richard K. Valicenti
303-777-2663
mhayden@christianacare.org
Facility: University of Colorado Hospital
Aurora, Colorado 80045
United States
Status: Recruiting Contact: Contact
Site Public Contact
719-365-2406
Dmiskin@Beebehealthcare.org
Facility: Rocky Mountain Cancer Centers-Boulder
Boulder, Colorado 80304
United States
Status: Recruiting Contact: Principal Investigator
Ramy F. Yaacoub
719-364-6700
jquiver1@jhmi.edu
Facility: UCHealth Memorial Hospital Central
Colorado Springs, Colorado 80909
United States
Status: Recruiting Contact: Contact
Site Public Contact
970-569-7429
yenrique@msmc.com
Facility: Memorial Hospital North
Colorado Springs, Colorado 80920
United States
Status: Recruiting Contact: Principal Investigator
Edmund W. Tai
970-297-6150
info@hawaiicancercare.com
Facility: Shaw Cancer Center
Edwards, Colorado 81632
United States
Status: Recruiting Contact: Contact
Site Public Contact
970-203-7083
i.webster@hawaiicancercare.com
Facility: Poudre Valley Hospital
Fort Collins, Colorado 80524
United States
Status: Recruiting Contact: Principal Investigator
Edmund W. Tai
203-785-5702
andersonj@illinoiscancercare.com
Facility: Cancer Care and Hematology-Fort Collins
Fort Collins, Colorado 80528
United States
Status: Recruiting Contact: Contact
Site Public Contact
860-545-5363
andersonj@illinoiscancercare.com
Facility: UCHealth Greeley Hospital
Greeley, Colorado 80631
United States
Status: Recruiting Contact: Principal Investigator
Edmund W. Tai
866-662-5678
andersonj@illinoiscancercare.com
Facility: Medical Center of the Rockies
Loveland, Colorado 80538
United States
Status: Recruiting Contact: Contact
Site Public Contact
860-224-5660
cancer@northwestern.edu
Facility: Smilow Cancer Hospital Care Center - Guiford
Guilford, Connecticut 06437
United States
Status: Recruiting Contact: Principal Investigator
Richard K. Valicenti
203-785-5702
clinical_trials@rush.edu
Facility: Hartford Hospital
Hartford, Connecticut 06102
United States
Status: Recruiting Contact: Contact
Site Public Contact
203-785-5702
morganthaler.jodi@mhsil.com
Facility: Midstate Medical Center
Meriden, Connecticut 06451
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
302-645-3100
Donald.Smith3@nm.org
Facility: The Hospital of Central Connecticut
New Britain, Connecticut 06050
United States
Status: Recruiting Contact: Contact
Site Public Contact
302-623-4450
morganthaler.jodi@mhsil.com
Facility: Yale University
New Haven, Connecticut 06520
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth R. Kessler
302-623-4450
andersonj@illinoiscancercare.com
Facility: Smilow Cancer Hospital Care Center-Trumbull
Trumbull, Connecticut 06611
United States
Status: Recruiting Contact: Contact
Site Public Contact
302-645-3100
andersonj@illinoiscancercare.com
Facility: Beebe South Coastal Health Campus
Frankford, Delaware 19945
United States
Status: Recruiting Contact: Principal Investigator
Nicholas DiBella
202-243-2373
Donald.Smith3@nm.org
Facility: Helen F Graham Cancer Center
Newark, Delaware 19713
United States
Status: Recruiting Contact: Contact
Site Public Contact
305-674-2625
andersonj@illinoiscancercare.com
Facility: Medical Oncology Hematology Consultants PA
Newark, Delaware 19713
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth R. Kessler
305-243-2647
andersonj@illinoiscancercare.com
Facility: Beebe Health Campus
Rehoboth Beach, Delaware 19971
United States
Status: Recruiting Contact: Contact
Site Public Contact
305-243-2647
andersonj@illinoiscancercare.com
Facility: Sibley Memorial Hospital
Washington, District of Columbia 20016
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth R. Kessler
305-243-2647
andersonj@illinoiscancercare.com
Facility: Mount Sinai Comprehensive Cancer Center at Aventura
Aventura, Florida 33180
United States
Status: Recruiting Contact: Contact
Site Public Contact
404-778-1868
andersonj@illinoiscancercare.com
Facility: UM Sylvester Comprehensive Cancer Center at Coral Gables
Coral Gables, Florida 33146
United States
Status: Recruiting Contact: Principal Investigator
Patricia H. Hardenbergh
404-851-7115
andersonj@illinoiscancercare.com
Facility: UM Sylvester Comprehensive Cancer Center at Deerfield Beach
Deerfield Beach, Florida 33442
United States
Status: Recruiting Contact: Contact
Site Public Contact
808-539-2273
andersonj@illinoiscancercare.com
Facility: University of Miami Miller School of Medicine-Sylvester Cancer Center
Miami, Florida 33136
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth R. Kessler
808-524-6115
Donald.Smith3@nm.org
Facility: Emory University Hospital/Winship Cancer Institute
Atlanta, Georgia 30322
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth R. Kessler
808-545-8548
ksoder@mcfarlandclinic.com
Facility: Emory Saint Joseph's Hospital
Atlanta, Georgia 30342
United States
Status: Recruiting Contact: Contact
Site Public Contact
808-522-4333
cancerresearch@mercydesmoines.org
Facility: Hawaii Cancer Care - Savio
'Aiea, Hawaii 96701
United States
Status: Recruiting Contact: Contact
Site Public Contact
808-547-6881
cancerresearch@mercydesmoines.org
Facility: Pali Momi Medical Center
'Aiea, Hawaii 96701
United States
Status: Recruiting Contact: Principal Investigator
Joseph W. Kim
309-243-3605
cancerresearch@mercydesmoines.org
Facility: The Cancer Center of Hawaii-Pali Momi
'Aiea, Hawaii 96701
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
cancerresearch@mercydesmoines.org
Facility: Hawaii Cancer Care Inc - Waterfront Plaza
Honolulu, Hawaii 96813
United States
Status: Recruiting Contact: Principal Investigator
Jessica M. Clement
309-243-3605
cancerresearch@mercydesmoines.org
Facility: Queen's Cancer Cenrer - POB I
Honolulu, Hawaii 96813
United States
Status: Recruiting Contact: Contact
Site Public Contact
312-695-1301
KUCC_Navigation@kumc.edu
Facility: Queen's Medical Center
Honolulu, Hawaii 96813
United States
Status: Recruiting Contact: Principal Investigator
Jessica M. Clement
312-942-5498
KUCC_Navigation@kumc.edu
Facility: Straub Clinic and Hospital
Honolulu, Hawaii 96813
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
KUCC_Navigation@kumc.edu
Facility: Queen's Cancer Center - Kuakini
Honolulu, Hawaii 96817
United States
Status: Recruiting Contact: Principal Investigator
Jessica M. Clement
630-352-5360
Keisha.humphries@ascension.org
Facility: The Cancer Center of Hawaii-Liliha
Honolulu, Hawaii 96817
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-876-4762
Cbcresearch@bhsi.com
Facility: Illinois CancerCare-Bloomington
Bloomington, Illinois 61704
United States
Status: Recruiting Contact: Principal Investigator
Joseph W. Kim
309-243-3605
emede1@lsuhsc.edu
Facility: Illinois CancerCare-Canton
Canton, Illinois 61520
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
emede1@lsuhsc.edu
Facility: Illinois CancerCare-Carthage
Carthage, Illinois 62321
United States
Status: Recruiting Contact: Principal Investigator
Joseph W. Kim
309-344-2831
ctsucontact@westat.com
Facility: Northwestern University
Chicago, Illinois 60611
United States
Status: Recruiting Contact: Contact
Site Public Contact
630-352-5360
LLemire@mmc.org
Facility: Rush University Medical Center
Chicago, Illinois 60612
United States
Status: Recruiting Contact: Principal Investigator
Gregory A. Masters
708-202-8387
OncClinicalResearch@mmc.org
Facility: Decatur Memorial Hospital
Decatur, Illinois 62526
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
ClinicalResearch@mmc.org
Facility: Northwestern Medicine Cancer Center Kishwaukee
DeKalb, Illinois 60115
United States
Status: Recruiting Contact: Principal Investigator
Gregory A. Masters
309-243-3605
LLemire@mmc.org
Facility: Crossroads Cancer Center
Effingham, Illinois 62401
United States
Status: Recruiting Contact: Contact
Site Public Contact
708-226-4357
wrighd@mmc.org
Facility: Illinois CancerCare-Eureka
Eureka, Illinois 61530
United States
Status: Recruiting Contact: Principal Investigator
Gregory A. Masters
309-243-3605
ClinicalResearch@mmc.org
Facility: Illinois CancerCare-Galesburg
Galesburg, Illinois 61401
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
jhcccro@jhmi.edu
Facility: Western Illinois Cancer Treatment Center
Galesburg, Illinois 61401
United States
Status: Recruiting Contact: Principal Investigator
Gregory A. Masters
309-243-3605
stephanie.couch@stjoeshealth.org
Facility: Northwestern Medicine Cancer Center Delnor
Geneva, Illinois 60134
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
crcwm-regulatory@crcwm.org
Facility: Edward Hines Jr VA Hospital
Hines, Illinois 60141
United States
Status: Recruiting Contact: Principal Investigator
Phuoc T. Tran
309-243-3605
stephanie.couch@stjoeshealth.org
Facility: Illinois CancerCare-Kewanee Clinic
Kewanee, Illinois 61443
United States
Status: Recruiting Contact: Contact
Site Public Contact
309-243-3605
stephanie.couch@stjoeshealth.org
Facility: Illinois CancerCare-Macomb
Macomb, Illinois 61455
United States
Status: Recruiting Contact: Principal Investigator
Michael A. Schwartz
309-243-3605
stephanie.couch@stjoeshealth.org
Facility: Loyola University Medical Center
Maywood, Illinois 60153
United States
Status: Recruiting Contact: Contact
Site Public Contact
217-788-3528
Rudi.Ross@usa.genesiscare.com
Facility: Illinois CancerCare-Ottawa Clinic
Ottawa, Illinois 61350
United States
Status: Recruiting Contact: Principal Investigator
Alan Libardi Dal Pra
630-352-5360
ctoadmin@karmanos.org
Facility: Illinois CancerCare-Pekin
Pekin, Illinois 61554
United States
Status: Recruiting Contact: Contact
Site Public Contact
937-528-2900
CTOResearch@hfhs.org
Facility: Illinois CancerCare-Peoria
Peoria, Illinois 61615
United States
Status: Recruiting Contact: Principal Investigator
Alan Libardi Dal Pra
515-239-4734
Rudi.Ross@usa.genesiscare.com
Facility: Methodist Medical Center of Illinois
Peoria, Illinois 61636
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-643-2196
ctoadmin@karmanos.org
Facility: OSF Saint Francis Medical Center
Peoria, Illinois 61637
United States
Status: Recruiting Contact: Principal Investigator
Alan Libardi Dal Pra
515-643-2196
crcwm-regulatory@crcwm.org
Facility: Illinois CancerCare-Peru
Peru, Illinois 61354
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-643-2196
stephanie.couch@stjoeshealth.org
Facility: Illinois CancerCare-Princeton
Princeton, Illinois 61356
United States
Status: Recruiting Contact: Principal Investigator
Ashesh B. Jani
515-241-6727
stephanie.couch@stjoeshealth.org
Facility: Memorial Medical Center
Springfield, Illinois 62781
United States
Status: Recruiting Contact: Principal Investigator
Ashesh B. Jani
515-643-2196
stephanie.couch@stjoeshealth.org
Facility: Northwestern Medicine Cancer Center Warrenville
Warrenville, Illinois 60555
United States
Status: Recruiting Contact: Contact
Site Public Contact
515-643-2196
stephanie.couch@stjoeshealth.org
Facility: Reid Health
Richmond, Indiana 47374
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-362-0070
crcwm-regulatory@crcwm.org
Facility: McFarland Clinic PC - Ames
Ames, Iowa 50010
United States
Status: Recruiting Contact: Contact
Site Public Contact
859-257-3379
mmcorc@healthpartners.com
Facility: Medical Oncology and Hematology Associates-West Des Moines
Clive, Iowa 50325
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
502-562-3429
CancerTrials@EssentiaHealth.org
Facility: Mercy Cancer Center-West Lakes
Clive, Iowa 50325
United States
Status: Recruiting Contact: Contact
Site Public Contact
502-897-8592
mmcorc@healthpartners.com
Facility: Greater Regional Medical Center
Creston, Iowa 50801
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
504-210-3539
mmcorc@healthpartners.com
Facility: Iowa Methodist Medical Center
Des Moines, Iowa 50309
United States
Status: Recruiting Contact: Contact
Site Public Contact
504-210-3539
coborncancercenter@centracare.com
Facility: Medical Oncology and Hematology Associates-Laurel
Des Moines, Iowa 50314
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
888-823-5923
mmcorc@healthpartners.com
Facility: Mercy Medical Center - Des Moines
Des Moines, Iowa 50314
United States
Status: Recruiting Contact: Contact
Site Public Contact
207-338-2500
mmcorc@healthpartners.com
Facility: Mercy Medical Center-West Lakes
West Des Moines, Iowa 50266
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
207-396-8670
sfmc@sfmc.net
Facility: University of Kansas Cancer Center
Kansas City, Kansas 66160
United States
Status: Recruiting Contact: Contact
Site Public Contact
207-885-7565
info@siteman.wustl.edu
Facility: University of Kansas Cancer Center-Overland Park
Overland Park, Kansas 66210
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
207-396-8670
KUCC_Navigation@kumc.edu
Facility: University of Kansas Hospital-Westwood Cancer Center
Westwood, Kansas 66205
United States
Status: Recruiting Contact: Contact
Site Public Contact
207-459-1600
KUCC_Navigation@kumc.edu
Facility: Ascension Via Christi Hospitals Wichita
Wichita, Kansas 67214
United States
Status: Recruiting Contact: Principal Investigator
David J. Tamura
207-396-8090
info@siteman.wustl.edu
Facility: Baptist Health Lexington
Lexington, Kentucky 40503
United States
Status: Recruiting Contact: Contact
Site Public Contact
207-396-8670
info@siteman.wustl.edu
Facility: University of Kentucky/Markey Cancer Center
Lexington, Kentucky 40536
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
410-955-8804
info@siteman.wustl.edu
Facility: The James Graham Brown Cancer Center at University of Louisville
Louisville, Kentucky 40202
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-726-5130
mccinfo@mtcancer.org
Facility: Baptist Health Louisville
Louisville, Kentucky 40207
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
877-442-3324
clinicaltrials@sfmc-gi.org
Facility: East Jefferson General Hospital
Metairie, Louisiana 70006
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
research@sncrf.org
Facility: LSU Healthcare Network / Metairie Multi-Specialty Clinic
Metairie, Louisiana 70006
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
800-865-1125
research@sncrf.org
Facility: MaineHealth Coastal Cancer Treatment Center
Bath, Maine 04530
United States
Status: Recruiting Contact: Contact
Site Public Contact
616-391-1230
research@sncrf.org
Facility: Waldo County General Hospital
Belfast, Maine 04915
United States
Status: Recruiting Contact: Principal Investigator
Sean Sachdev
734-712-3671
research@sncrf.org
Facility: MaineHealth/SMHC Cancer Care and Blood Disorders-Biddeford
Biddeford, Maine 04005
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-865-1125
research@sncrf.org
Facility: Stephens Memorial Hospital
Norway, Maine 04268
United States
Status: Recruiting Contact: Principal Investigator
Dian Wang
734-712-3671
research@sncrf.org
Facility: Maine Medical Center-Bramhall Campus
Portland, Maine 04102
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
research@sncrf.org
Facility: Penobscot Bay Medical Center
Rockport, Maine 04856
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
941-833-5700
research@sncrf.org
Facility: MaineHealth Cancer Care Center of York County
Sanford, Maine 04073
United States
Status: Recruiting Contact: Contact
Site Public Contact
248-551-7695
cancer.research.nurse@dartmouth.edu
Facility: MaineHealth/SMHC Cancer Care and Blood Disorders-Sanford
Sanford, Maine 04073
United States
Status: Recruiting Contact: Principal Investigator
Christopher M. George
313-576-9790
eskwak@montefiore.org
Facility: Maine Medical Center- Scarborough Campus
Scarborough, Maine 04074
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-916-3721
eskwak@montefiore.org
Facility: Maine Medical Partners - South Portland
South Portland, Maine 04106
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
941-833-5700
eskwak@montefiore.org
Facility: Johns Hopkins University/Sidney Kimmel Cancer Center
Baltimore, Maryland 21287
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-576-9790
protocols@swog.org
Facility: Massachusetts General Hospital Cancer Center
Boston, Massachusetts 02114
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
248-551-7695
karen.morris@unchealth.unc.edu
Facility: Dana-Farber Cancer Institute
Boston, Massachusetts 02215
United States
Status: Recruiting Contact: Contact
Site Public Contact
616-391-1230
Carla.Zimmerman@vidanthealth.com
Facility: Saint Joseph Mercy Hospital
Ann Arbor, Michigan 48106
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
734-712-3671
Carla.Zimmerman@vidanthealth.com
Facility: University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan 48109
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
OncologyClinicalTrialsFargo@sanfordhealth.org
Facility: Bronson Battle Creek
Battle Creek, Michigan 49017
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
941-833-5700
OncologyClinicalTrialsFargo@sanfordhealth.org
Facility: Saint Joseph Mercy Brighton
Brighton, Michigan 48114
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
OncologyClinicalTrialsFargo@sanfordhealth.org
Facility: University of Michigan - Brighton Center for Specialty Care
Brighton, Michigan 48116
United States
Status: Recruiting Contact: Principal Investigator
Christopher M. George
248-551-7695
cancer@uchealth.com
Facility: Saint Joseph Mercy Canton
Canton, Michigan 48188
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
dstrater@metrohealth.org
Facility: Saint Joseph Mercy Chelsea
Chelsea, Michigan 48118
United States
Status: Recruiting Contact: Principal Investigator
Elizabeth Henry
616-391-1230
Jamesline@osumc.edu
Facility: GenesisCare USA - Clarkston
Clarkston, Michigan 48346
United States
Status: Recruiting Contact: Contact
Site Public Contact
248-551-7695
clinical.trials@daytonncorp.org
Facility: Beaumont Hospital - Dearborn
Dearborn, Michigan 48124
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
941-833-5700
cancer@uchealth.com
Facility: Wayne State University/Karmanos Cancer Institute
Detroit, Michigan 48201
United States
Status: Recruiting Contact: Contact
Site Public Contact
313-916-3721
ou-clinical-trials@ouhsc.edu
Facility: Henry Ford Hospital
Detroit, Michigan 48202
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
616-391-1230
trials@ohsu.edu
Facility: GenesisCare USA - Farmington Hills
Farmington Hills, Michigan 48334
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-333-5000
stephanie.couch@stjoeshealth.org
Facility: Weisberg Cancer Treatment Center
Farmington Hills, Michigan 48334
United States
Status: Recruiting Contact: Principal Investigator
Ami Badami
952-993-1517
protocols@swog.org
Facility: Beaumont Hospital - Farmington Hills
Farmington Hills, Michigan 48336
United States
Status: Recruiting Contact: Contact
Site Public Contact
218-786-3308
haneydl@upmc.edu
Facility: West Michigan Cancer Center
Kalamazoo, Michigan 49007
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
952-993-1517
stephanie.couch@stjoeshealth.org
Facility: Sparrow Hospital
Lansing, Michigan 48912
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
protocols@swog.org
Facility: Saint Mary Mercy Hospital
Livonia, Michigan 48154
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
855-776-0015
HemonCCTrials@geisinger.edu
Facility: GenesisCare USA - Madison Heights
Madison Heights, Michigan 48071
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-229-4907
protocols@swog.org
Facility: 21st Century Oncology-Pontiac
Pontiac, Michigan 48341
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
952-993-1517
klitchfield@PINNACLEHEALTH.org
Facility: William Beaumont Hospital-Royal Oak
Royal Oak, Michigan 48073
United States
Status: Recruiting Contact: Contact
Site Public Contact
952-993-1517
CTO@hmc.psu.edu
Facility: Ascension Saint Mary's Hospital
Saginaw, Michigan 48601
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
573-334-2230
HemonCCTrials@geisinger.edu
Facility: Munson Medical Center
Traverse City, Michigan 49684
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
protocols@swog.org
Facility: William Beaumont Hospital - Troy
Troy, Michigan 48085
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
913-588-3671
cancer@washingtonhospital.org
Facility: GenesisCare USA - Troy
Troy, Michigan 48098
United States
Status: Recruiting Contact: Contact
Site Public Contact
913-588-3671
HemonCCTrials@geisinger.edu
Facility: Henry Ford West Bloomfield Hospital
West Bloomfield, Michigan 48322
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
800-600-3606
hcc-clinical-trials@musc.edu
Facility: Metro Health Hospital
Wyoming, Michigan 49519
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-600-3606
kmertz-rivera@gibbscc.org
Facility: Sanford Joe Lueken Cancer Center
Bemidji, Minnesota 56601
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
314-996-5569
OncologyClinicTrialsSF@sanfordhealth.org
Facility: Mercy Hospital
Coon Rapids, Minnesota 55433
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-251-7066
OncologyClinicalTrialsSF@SanfordHealth.org
Facility: Miller-Dwan Hospital
Duluth, Minnesota 55805
United States
Status: Recruiting Contact: Principal Investigator
Bryan A. Faller
800-600-3606
canceranswerline@UTSouthwestern.edu
Facility: Fairview Southdale Hospital
Edina, Minnesota 55435
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569
burton@bcm.edu
Facility: Unity Hospital
Fridley, Minnesota 55432
United States
Status: Recruiting Contact: Principal Investigator
Christopher M. George
314-996-5569
Suzanne.cole@utsouthwestern.edu
Facility: Mayo Clinic in Rochester
Rochester, Minnesota 55905
United States
Status: Recruiting Contact: Contact
Site Public Contact
314-996-5569
cancertrialsinfo@hsc.wvu.edu
Facility: Coborn Cancer Center at Saint Cloud Hospital
Saint Cloud, Minnesota 56303
United States
Status: Recruiting Contact: Principal Investigator
Howard M. Gross
406-969-6060
Juli.Alford@aspirus.org
Facility: Park Nicollet Clinic - Saint Louis Park
Saint Louis Park, Minnesota 55416
United States
Status: Recruiting Contact: Contact
Site Public Contact
308-398-6518
CancerTrials@EssentiaHealth.org
Facility: Regions Hospital
Saint Paul, Minnesota 55101
United States
Status: Recruiting Contact: Principal Investigator
Debra M. Prow
402-354-5144
oncology.clinical.trials@marshfieldresearch.org
Facility: Saint Francis Medical Center
Cape Girardeau, Missouri 63703
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
702-384-0013
ncorp@aurora.org
Facility: Siteman Cancer Center at West County Hospital
Creve Coeur, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
ncorp@aurora.org
Facility: University of Kansas Cancer Center - North
Kansas City, Missouri 64154
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
702-384-0013
ncorp@aurora.org
Facility: University of Kansas Cancer Center - Lee's Summit
Lee's Summit, Missouri 64064
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
oncology.clinical.trials@marshfieldresearch.org
Facility: Washington University School of Medicine
Saint Louis, Missouri 63110
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
702-384-0013
Beth.Knetter@aspirus.org
Facility: Siteman Cancer Center-South County
Saint Louis, Missouri 63129
United States
Status: Recruiting Contact: Contact
Site Public Contact
702-384-0013
ncorp@aurora.org
Facility: Missouri Baptist Medical Center
Saint Louis, Missouri 63131
United States
Status: Recruiting Contact: Principal Investigator
Joshua Lukenbill
702-384-0013
oncology.clinical.trials@marshfieldresearch.org
Facility: Mercy Hospital Saint Louis
Saint Louis, Missouri 63141
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-639-6918
mmcorc@healthpartners.com
Facility: Siteman Cancer Center at Saint Peters Hospital
Saint Peters, Missouri 63376
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
201-996-2879
ncorp@aurora.org
Facility: Sainte Genevieve County Memorial Hospital
Sainte Genevieve, Missouri 63670
United States
Status: Recruiting Contact: Contact
Site Public Contact
718-379-6866
oncology.clinical.trials@marshfieldresearch.org
Facility: Missouri Baptist Sullivan Hospital
Sullivan, Missouri 63080
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
718-379-6866
oncology.clinical.trials@marshfieldresearch.org
Facility: Missouri Baptist Outpatient Center-Sunset Hills
Sunset Hills, Missouri 63127
United States
Status: Recruiting Contact: Contact
Site Public Contact
718-379-6866
oncology.clinical.trials@marshfieldresearch.org
Facility: Benefis Healthcare- Sletten Cancer Institute
Great Falls, Montana 59405
United States
Status: Recruiting Contact: Principal Investigator
Richard L. Deming
516-734-8896
Facility: CHI Health Good Samaritan
Kearney, Nebraska 68847
United States
Status: Recruiting Contact: Contact
Site Public Contact
212-639-7592
Facility: Nebraska Methodist Hospital
Omaha, Nebraska 68114
United States
Status: Recruiting Contact: Principal Investigator
Xinglei Shen
585-341-8113
Facility: OptumCare Cancer Care at Charleston
Las Vegas, Nevada 89102
United States
Status: Recruiting Contact: Contact
Site Public Contact
585-275-5830
Facility: Radiation Oncology Centers of Nevada Central
Las Vegas, Nevada 89106
United States
Status: Recruiting Contact: Principal Investigator
Xinglei Shen
800-862-2215
Facility: Comprehensive Cancer Centers of Nevada - Northwest
Las Vegas, Nevada 89128
United States
Status: Recruiting Contact: Contact
Site Public Contact
828-696-4716
Facility: Comprehensive Cancer Centers of Nevada - Town Center
Las Vegas, Nevada 89144
United States
Status: Recruiting Contact: Principal Investigator
Xinglei Shen
252-559-2201
Facility: Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada 89148
United States
Status: Recruiting Contact: Contact
Site Public Contact
252-559-2201
Facility: OptumCare Cancer Care at Fort Apache
Las Vegas, Nevada 89148
United States
Status: Recruiting Contact: Principal Investigator
Shaker R. Dakhil
701-323-5760
Facility: Comprehensive Cancer Centers of Nevada - Central Valley
Las Vegas, Nevada 89169
United States
Status: Recruiting Contact: Contact
Site Public Contact
701-323-5760
Facility: Renown Regional Medical Center
Reno, Nevada 89502
United States
Status: Recruiting Contact: Principal Investigator
Andrew J. Hart
701-234-6161
Facility: Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire 03756
United States
Status: Recruiting Contact: Contact
Site Public Contact
513-584-7698
Facility: Hackensack University Medical Center
Hackensack, New Jersey 07601
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-293-5066
Facility: Montefiore Medical Center-Einstein Campus
Bronx, New York 10461
United States
Status: Recruiting Contact: Contact
Site Public Contact
513-584-7698
Facility: Montefiore Medical Center-Weiler Hospital
Bronx, New York 10461
United States
Status: Recruiting Contact: Principal Investigator
Andrew J. Hart
877-231-4440
Facility: Montefiore Medical Center - Moses Campus
Bronx, New York 10467
United States
Status: Recruiting Contact: Contact
Site Public Contact
405-271-8777
Facility: Northwell Health/Center for Advanced Medicine
Lake Success, New York 11042
United States
Status: Recruiting Contact: Principal Investigator
Scott E. Delacroix
503-494-1080
Facility: Memorial Sloan Kettering Cancer Center
New York, New York 10065
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
Facility: Highland Hospital
Rochester, New York 14620
United States
Status: Recruiting Contact: Principal Investigator
Scott E. Delacroix
412-389-5208
Facility: University of Rochester
Rochester, New York 14642
United States
Status: Recruiting Contact: Contact
Site Public Contact
734-712-3671
Facility: Phelps Memorial Hospital Center
Sleepy Hollow, New York 10591
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
570-271-5251
Facility: Stony Brook University Medical Center
Stony Brook, New York 11794
United States
Status: Recruiting Contact: Contact
Site Public Contact
724-838-1900
Facility: Margaret R Pardee Memorial Hospital
Hendersonville, North Carolina 28791
United States
Status: Recruiting Contact: Contact
Site Public Contact
717-531-3779
Facility: Vidant Oncology-Kenansville
Kenansville, North Carolina 28349
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
814-534-4724
Facility: Vidant Oncology-Kinston
Kinston, North Carolina 28501
United States
Status: Recruiting Contact: Contact
Site Public Contact
570-374-8555
Facility: Sanford Bismarck Medical Center
Bismarck, North Dakota 58501
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-604-2020
Facility: Sanford Broadway Medical Center
Fargo, North Dakota 58122
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
412-647-2811
Facility: Sanford Roger Maris Cancer Center
Fargo, North Dakota 58122
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-784-4900
Facility: University of Cincinnati Cancer Center-UC Medical Center
Cincinnati, Ohio 45219
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
412-647-8073
Facility: MetroHealth Medical Center
Cleveland, Ohio 44109
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-621-2334
Facility: Ohio State University Comprehensive Cancer Center
Columbus, Ohio 43210
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
412-367-6454
Facility: Kettering Medical Center
Kettering, Ohio 45429
United States
Status: Recruiting Contact: Contact
Site Public Contact
412-502-3920
Facility: University of Cincinnati Cancer Center-West Chester
West Chester, Ohio 45069
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
814-676-7900
Facility: Cancer Centers of Southwest Oklahoma Research
Lawton, Oklahoma 73505
United States
Status: Recruiting Contact: Contact
Site Public Contact
724-437-2503
Facility: University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma 73104
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
724-223-3788
Facility: Oregon Health and Science University
Portland, Oregon 97239
United States
Status: Recruiting Contact: Contact
Site Public Contact
570-271-5251
Facility: Lehigh Valley Hospital-Cedar Crest
Allentown, Pennsylvania 18103
United States
Status: Recruiting Contact: Principal Investigator
Matthew D. Cheney
717-724-6760
Facility: UPMC Altoona
Altoona, Pennsylvania 16601
United States
Status: Recruiting Contact: Contact
Site Public Contact
843-792-9321
Facility: UPMC-Heritage Valley Health System Beaver
Beaver, Pennsylvania 15009
United States
Status: Recruiting Contact: Principal Investigator
Phuoc T. Tran
864-241-6251
Facility: Lehigh Valley Hospital - Muhlenberg
Bethlehem, Pennsylvania 18017
United States
Status: Recruiting Contact: Contact
Site Public Contact
864-560-6104
Facility: Carlisle Regional Cancer Center
Carlisle, Pennsylvania 17015
United States
Status: Recruiting Contact: Principal Investigator
Jason A. Efstathiou
605-312-3320
Facility: Geisinger Medical Center
Danville, Pennsylvania 17822
United States
Status: Recruiting Contact: Contact
Site Public Contact
605-312-3320
Facility: UPMC Cancer Center at UPMC Horizon
Farrell, Pennsylvania 16121
United States
Status: Recruiting Contact: Principal Investigator
Kent W. Mouw
800-811-8480
Facility: UPMC Cancer Centers - Arnold Palmer Pavilion
Greensburg, Pennsylvania 15601
United States
Status: Recruiting Contact: Contact
Site Public Contact
214-648-7097
Facility: UPMC Pinnacle Cancer Center/Community Osteopathic Campus
Harrisburg, Pennsylvania 17109
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
713-798-1354
Facility: Penn State Milton S Hershey Medical Center
Hershey, Pennsylvania 17033-0850
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-553-2278
Facility: UPMC-Johnstown/John P. Murtha Regional Cancer Center
Johnstown, Pennsylvania 15901
United States
Status: Recruiting Contact: Principal Investigator
Samuel D. Kaffenberger
972-669-7044
Facility: Geisinger Medical Oncology-Lewisburg
Lewisburg, Pennsylvania 17837
United States
Status: Recruiting Contact: Contact
Site Public Contact
425-899-6000
Facility: UPMC Cancer Center at UPMC McKeesport
McKeesport, Pennsylvania 15132
United States
Status: Recruiting Contact: Principal Investigator
Kathleen J. Yost
800-804-8824
Facility: UPMC Cancer Center - Monroeville
Monroeville, Pennsylvania 15146
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
304-293-7374
Facility: UPMC-Coraopolis/Heritage Valley Radiation Oncology
Moon, Pennsylvania 15108
United States
Status: Recruiting Contact: Contact
Site Public Contact
715-623-9869
Facility: UPMC-Magee Womens Hospital
Pittsburgh, Pennsylvania 15213
United States
Status: Recruiting Contact: Principal Investigator
Samuel D. Kaffenberger
218-786-3308
Facility: UPMC-Saint Margaret
Pittsburgh, Pennsylvania 15215
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
Facility: University of Pittsburgh Cancer Institute (UPCI)
Pittsburgh, Pennsylvania 15232
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
855-776-0015
Facility: UPMC-Shadyside Hospital
Pittsburgh, Pennsylvania 15232
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: UPMC-Passavant Hospital
Pittsburgh, Pennsylvania 15237
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi
920-435-8326
Facility: UPMC-Saint Clair Hospital Cancer Center
Pittsburgh, Pennsylvania 15243
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: UPMC Cancer Center at UPMC Northwest
Seneca, Pennsylvania 16346
United States
Status: Recruiting Contact: Principal Investigator
Frank A. Vicini
414-302-2304
Facility: UPMC Uniontown Hospital Radiation Oncology
Uniontown, Pennsylvania 15401
United States
Status: Recruiting Contact: Contact
Site Public Contact
855-776-0015
Facility: UPMC Washington Hospital Radiation Oncology
Washington, Pennsylvania 15301
United States
Status: Recruiting Contact: Principal Investigator
Daniel J. Krauss
414-302-2304
Facility: Geisinger Wyoming Valley/Henry Cancer Center
Wilkes-Barre, Pennsylvania 18711
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
Facility: UPMC Memorial
York, Pennsylvania 17408
United States
Status: Recruiting Contact: Principal Investigator
Nitin G. Vaishampayan
715-847-2353
Facility: Medical University of South Carolina
Charleston, South Carolina 29425
United States
Status: Recruiting Contact: Contact
Site Public Contact
414-302-2304
Facility: Prisma Health Cancer Institute - Faris
Greenville, South Carolina 29605
United States
Status: Recruiting Contact: Principal Investigator
Ding Wang
800-782-8581
Facility: Spartanburg Medical Center
Spartanburg, South Carolina 29303
United States
Status: Recruiting Contact: Contact
Site Public Contact
800-782-8581
Facility: Sanford Cancer Center Oncology Clinic
Sioux Falls, South Dakota 57104
United States
Status: Recruiting Contact: Principal Investigator
Nitin G. Vaishampayan
800-782-8581
Facility: Sanford USD Medical Center - Sioux Falls
Sioux Falls, South Dakota 57117-5134
United States
Status: Recruiting Contact: Contact
Site Public Contact
877-405-6866
Facility: Vanderbilt University/Ingram Cancer Center
Nashville, Tennessee 37232
United States
Status: Recruiting Contact: Principal Investigator
Daniel J. Krauss
888-799-3989
Facility: UT Southwestern/Simmons Cancer Center-Dallas
Dallas, Texas 75390
United States
Status: Recruiting Contact: Contact
Site Public Contact
715-422-7718
Facility: Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, Texas 77030
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Michael E DeBakey VA Medical Center
Houston, Texas 77030
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi

Facility: UT Southwestern Clinical Center at Richardson/Plano
Richardson, Texas 75080
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Seattle Cancer Care Alliance at EvergreenHealth
Kirkland, Washington 98034
United States
Status: Recruiting Contact: Principal Investigator
Tareq Al Baghdadi

Facility: Seattle Cancer Care Alliance
Seattle, Washington 98109
United States
Status: Recruiting Contact: Principal Investigator
Daniel J. Krauss

Facility: University of Washington Medical Center - Montlake
Seattle, Washington 98195
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: West Virginia University Healthcare
Morgantown, West Virginia 26506
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Langlade Hospital and Cancer Center
Antigo, Wisconsin 54409
United States
Status: Recruiting Contact: Principal Investigator
Kathleen J. Yost

Facility: Northwest Wisconsin Cancer Center
Ashland, Wisconsin 54806
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Marshfield Medical Center-EC Cancer Center
Eau Claire, Wisconsin 54701
United States
Status: Recruiting Contact: Principal Investigator
Daniel J. Krauss

Facility: Mayo Clinic Health System-Eau Claire Clinic
Eau Claire, Wisconsin 54701
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Aurora Cancer Care-Grafton
Grafton, Wisconsin 53024
United States
Status: Recruiting Contact: Principal Investigator
Frank A. Vicini

Facility: Bellin Memorial Hospital
Green Bay, Wisconsin 54301
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Aurora BayCare Medical Center
Green Bay, Wisconsin 54311
United States
Status: Recruiting Contact: Principal Investigator
Ding Wang

Facility: Aurora Cancer Care-Kenosha South
Kenosha, Wisconsin 53142
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Mayo Clinic Health System-Franciscan Healthcare
La Crosse, Wisconsin 54601
United States
Status: Recruiting Contact: Principal Investigator
Kathleen J. Yost

Facility: Aurora Bay Area Medical Group-Marinette
Marinette, Wisconsin 54143
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Marshfield Medical Center-Marshfield
Marshfield, Wisconsin 54449
United States
Status: Recruiting Contact: Principal Investigator
Preston D. Steen

Facility: Aspirus Medford Hospital
Medford, Wisconsin 54451
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Aurora Saint Luke's Medical Center
Milwaukee, Wisconsin 53215
United States
Status: Recruiting Contact: Principal Investigator
David M. King

Facility: Marshfield Clinic-Minocqua Center
Minocqua, Wisconsin 54548
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Cancer Center of Western Wisconsin
New Richmond, Wisconsin 54017
United States
Status: Recruiting Contact: Principal Investigator
Bret E. Friday

Facility: Vince Lombardi Cancer Clinic - Oshkosh
Oshkosh, Wisconsin 54904
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Marshfield Medical Center-Rice Lake
Rice Lake, Wisconsin 54868
United States
Status: Recruiting Contact: Principal Investigator
David M. King

Facility: Marshfield Clinic Stevens Point Center
Stevens Point, Wisconsin 54482
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Aspirus Regional Cancer Center
Wausau, Wisconsin 54401
United States
Status: Recruiting Contact: Principal Investigator
David M. King

Facility: Diagnostic and Treatment Center
Weston, Wisconsin 54476
United States
Status: Recruiting Contact: Contact
Site Public Contact

Facility: Aspirus Cancer Care - Wisconsin Rapids
Wisconsin Rapids, Wisconsin 54494
United States
Status: Recruiting Contact: Contact
Site Public Contact